• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Glenmark Pharma gets ANDA approval for Tacrolimus Capsules

expresspharmaNovember 12, 2020

Tag: ANDA , Glenmark , Astellas , Tacrolimus Capsules

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (US FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.

According to IQVIA, sales data for the 12 month period ending September 2020, the Prograf Capsules, 0.5 mg, 1 mg and 5 mg market2 achieved annual sales of approximately $286.8 million.

Glenmark’s current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Sputnik V vaccine shows 92 per cent efficacy in ongoing phase III trials in Russia

Next:SCHOTT Glass India inaugurates new glass melting tank at Gujarat facility

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Glenmark Pharma gets ANDA approval for Tacrolimus Capsules | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING

The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING
High-standard Influenza Vaccine (Split virion), inactivated

High-standard Influenza Vaccine (Split virion), inactivated
Pressure vessel and non - standard series

Pressure vessel and non - standard series
LGJ-200F Standard Type Pilot Freeze Dryer

LGJ-200F Standard Type Pilot Freeze Dryer
Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard and Produce

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard and Produce
High-standard and high quality Influenza Vaccine (Split virion), inactivated

High-standard and high quality Influenza Vaccine (Split virion), inactivated
GMP Standard Factory Supply Amygdalin 98%

GMP Standard Factory Supply Amygdalin 98%

International standard Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect

International standard Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect
Particle Size Standards

Particle Size Standards
American standard Japanese standard German standard gate valve

American standard Japanese standard German standard gate valve

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service